The Impact of Angiotensin System Inhibitors on Outcomes in Patients with mRCC

January 31, 2014
Rana R. McKay, MD

Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, Boston, Massachusetts, discusses a trial that analyzed overall survival in patients with metastatic renal cell carcinoma who used angiotensin system inhibitors.

Clinical Pearls

Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, Boston, Massachusetts, discusses a trial that analyzed overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) who used angiotensin system inhibitors (ASI).Read more about this trial > >

  • This study evaluated OS in ASI users versus nonusers in patients with mRCC
  • OS was 27 months compared to 17 months (ASI users vs nonusers, respectively; hazard ratio=1.2)
  • In a subset analysis stratified by types of therapy for mRCC (including VEGF-targeted therapy, mTOR-targeted therapy, and IFN-α therapy), the only statistically significant OS benefit was seen in patients receiving VEGF-targeted therapy

<<<

Back to the GU 2014 conference page